Faeth Therapeutics, Inc. - 10-Q Filing

Faeth Therapeutics reports Q3 financial position characterized by ongoing R&D and G&A expenses with significant equity-based compensation activity.

SEC EDGAR ·

Tickers: $SNSE

Read the full article at SEC EDGAR

More Regulatory news